GnRH Agonist and Intrauterine Insemination

The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intrauterine Insemination

Age range

18 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Instituto Valenciano de Infertilidad Spain

Valencia, 46015, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women < 38 years old
Bilateral tubal patency confirmed by hysterosonography
Normal ultrasound scan of uterus and ovaries
Normal day 3 basal hormones
Motile sperm count after capacitation ≥ 3 mill/ml

Exclusion criteria

Endometriosis
Polycystic ovary syndrome
Uterine disease (polyps, myomas and müllerian diseases)

Treatment and study plan

Tryptorelin

Drug

Sponsors and collaborators

Lead sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA

Other

Registry information

Official study title

Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2007
First posted: Jul 18, 2007
Registry last updated: Sep 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed